Citalopram and bupropion-SR: Combining versus switching in patients with treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 65, Issue 3, 2004, Pages 337-340

  Lam, Raymond W ^a,b   Hossie, Helen ^c   Solomons, Kevin ^a,b   Yatham, Lakshmi N ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH   (Canada)

^c Mental Health Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DELAYED RELEASE FORMULATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COMBINATION; DRUG RESISTANCE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; QUESTIONNAIRE;

ADULT; ANTIDEPRESSIVE AGENTS; BUPROPION; CITALOPRAM; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS;

EID: 2342524603     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0308     Document Type: Article

References (24)

1. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51(suppl 6):39-47 (Pubitemid 20212863)
2. Fava M, Davidson KG. Definition and epidemiology of treatmentresistant depression. Psychiatr Clin North Am 1996;19:179-200
3. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097
4. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):10-17 (Pubitemid 32685967)
5. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):26-31 (Pubitemid 32685969)
6. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963-971 (Pubitemid 35388053)
7. Thase ME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 2001;62:221-224 (Pubitemid 32428758)
8. Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders, 4: medications and other biological treatments. Can J Psychiatry 2001;46(suppl 1):38S-58S
9. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001;62(suppl 18):12-17 (Pubitemid 33736200)
10. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58 (suppl 13):23-29 (Pubitemid 28011969)
11. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15 (Pubitemid 30104377)
12. Mischoulon D, Nierenberg AA, Kizilbash L, et al. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000;45:476-481
13. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999;60(suppl 4):4-11 (Pubitemid 29143096)
14. Lam RW, Wan DD, Cohen NL, et al. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002;63: 685-693 (Pubitemid 34898432)
15. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
16. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 1996;16:80-81 (Pubitemid 26060755)
17. Bodkin JA, Lasser RA, Wines JDJ, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145 (Pubitemid 27199778)
18. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety 1998;7:73-75 (Pubitemid 28235117)
19. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63:181-186 (Pubitemid 34407075)
20. National Institute of Mental Health. Clinical Global Impressions (CGI) scale. Psychopharmacol Bull 1985;21:839-843
21. Williams JBW, Link MJ, Rosenthal NE, et al. Structured Interview Guide for the Hamilton Depression Rating Scale: Seasonal Affective Disorders Version (SIGH-SAD). New York, NY: New York Psychiatric Institute; 1988
22. Dewan MJ, Anand VS. Evaluating the tolerability of the newer antidepressants. J Nerv Ment Dis 1999;187:96-101 (Pubitemid 29091765)
23. Pollock BG, Sweet RA, Kirshner M, et al. Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 1996;18:581-585 (Pubitemid 26330480)
24. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 2002;24:436-437 (Pubitemid 34553212)